These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 20065181)

  • 1. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
    Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
    J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.
    Kopek N; Paludan M; Petersen J; Hansen AT; Grau C; Høyer M
    Radiother Oncol; 2009 Dec; 93(3):402-7. PubMed ID: 19559492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
    Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
    Baumann P; Nyman J; Hoyer M; Wennberg B; Gagliardi G; Lax I; Drugge N; Ekberg L; Friesland S; Johansson KA; Lund JA; Morhed E; Nilsson K; Levin N; Paludan M; Sederholm C; Traberg A; Wittgren L; Lewensohn R
    J Clin Oncol; 2009 Jul; 27(20):3290-6. PubMed ID: 19414667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.
    Shennib H; Bogart J; Herndon JE; Kohman L; Keenan R; Green M; Sugarbaker D; ;
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):813-8. PubMed ID: 15821648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure.
    Andratschke N; Zimmermann F; Boehm E; Schill S; Schoenknecht C; Thamm R; Molls M; Nieder C; Geinitz H
    Radiother Oncol; 2011 Nov; 101(2):245-9. PubMed ID: 21724287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections.
    Sienel W; Dango S; Kirschbaum A; Cucuruz B; Hörth W; Stremmel C; Passlick B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):728-34. PubMed ID: 18261918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
    Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
    Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery.
    Palma D; Visser O; Lagerwaard FJ; Belderbos J; Slotman B; Senan S
    Radiother Oncol; 2011 Nov; 101(2):240-4. PubMed ID: 21775007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.
    Henderson M; McGarry R; Yiannoutsos C; Fakiris A; Hoopes D; Williams M; Timmerman R
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):404-9. PubMed ID: 18394819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
    Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.
    Carr SR; Schuchert MJ; Pennathur A; Wilson DO; Siegfried JM; Luketich JD; Landreneau RJ
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):390-7. PubMed ID: 22169444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis.
    Louie AV; Rodrigues G; Hannouf M; Lagerwaard F; Palma D; Zaric GS; Haasbeek C; Senan S
    Radiother Oncol; 2011 May; 99(2):161-5. PubMed ID: 21620503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.